This article is more than 5 years old. Information may no longer be current.

Nicox reports total revenues of €4.5 million in first 9 months of 2014

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Nicox reported total revenues of €4.5 million for the first 9 months of 2014, compared with €0.3 million a year ago, according to a press release.

Sales were €0.8 million in the United States and €3.2 million in Europe and the rest of world. Revenues also included a €0.5 million upfront payment related to an exclusive distribution agreement with Nitto Medic regarding the commercialization of AdenoPlus in Japan.

Cash, cash equivalents and current financial instruments totaled €32.9 million, while bank indebtedness was €0.3 million after consolidation of new entities.

In the third quarter, Nicox acquired Aciex Therapeutics, Doliage and the Carragelose antiviral eye drop program. In October, it launched Xailin Gel in Europe.